Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors, other available therapies have limited benefit. Preclinical evidences showed a cross-talk between the mTOR pathway and estrogen receptor signaling. This provided a rationale for adding an antiestrogen treatment in female patients becoming resistant to mTOR inhibitors.
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors / R. Sanfilippo, C. Fabbroni, G. Fucà, E. Fumagalli, C. Morosi, M. Sbaraglia, A. Gronchi, P. Collini, A.P. Dei Tos, P.G. Casali. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 26:20(2020 Oct 15), pp. 5534-5538.
Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors
R. SanfilippoPrimo
;C. FabbroniSecondo
;E. Fumagalli;P.G. CasaliUltimo
2020
Abstract
Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors, other available therapies have limited benefit. Preclinical evidences showed a cross-talk between the mTOR pathway and estrogen receptor signaling. This provided a rationale for adding an antiestrogen treatment in female patients becoming resistant to mTOR inhibitors.
| File | Dimensione | Formato | |
|---|---|---|---|
|
5534.full(1).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.07 MB
Formato
Adobe PDF
|
1.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
